Fighting a generic onslaught, Novartis adds CAR-T to its growing list of late-stage blockbusters
One of the reasons why Novartis isn’t being forced to bid into the stratosphere for late-stage drugs is that its industry-topping R&D budget — $9 billion last year — has already funded one of the biggest late-stage pipelines in the industry. The pharma giant underscored that today as it outlined 13 prospective blockbusters with upcoming pivotal readouts in the coming months and years, a group that now includes its lead CAR-T therapy for the very first time. And it added more details on its immuno-oncology strategy, which has lagged behind leaders like Merck, Bristol-Myers Squibb and Roche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
